Jones T P, Brennan P C, Ryan E
Medical Imaging Optimisation and Perception Group (MIOPeG), Discipline of Medical Radiation Sciences, Faculty of Health Science, University of Sydney, 75 East Street, Lidcombe, NSW2141, Australia.
Radiat Prot Dosimetry. 2017 Nov 1;176(3):252-257. doi: 10.1093/rpd/ncx003.
This study examines the cumulative radiation dose levels received by a group of children who underwent multiple cardiac catheterisation procedures during the investigation and management of congenital heart disease (CHD). The purpose is to calculate cumulative doses, identify higher dose individuals, outline the inconsistencies with risk assessment and encourage the establishment of dose databases in order to facilitate the longitudinal research necessary to better understand health risks. A retrospective review of patient records for 117 paediatric patients who have undergone two or more cardiac catheterisations for the investigation of CHD was undertaken. This cohort consisted of patients who were catheterised over a period from September 2002 to August 2014. The age distribution was from newborn to 17 y. Archived kerma-area product (PKA) and fluoroscopy time (T) readings were retrieved and analysed. Cumulative effective and individual organ doses were determined. The cumulative PKA levels ranged from 1.8 to 651.2 Gycm2, whilst cumulative effective dose levels varied from 2 to 259 mSv. The cumulative fluoroscopy time was shown to vary from 8.1 to 193.5 min. Median cumulative organ doses ranged from 3 to 94 mGy. Cumulative effective dose levels are highly variable but may exceed 250 mSv. Individual organ and effective dose measurements remain useful for comparison purposes between institutions although current methodologies used for determining lifetime risks are inadequate.
本研究调查了一组在先天性心脏病(CHD)的检查和治疗过程中接受多次心导管插入术的儿童所接受的累积辐射剂量水平。目的是计算累积剂量,识别高剂量个体,概述与风险评估的不一致之处,并鼓励建立剂量数据库,以便开展必要的纵向研究,从而更好地了解健康风险。对117例因CHD检查而接受过两次或更多次心导管插入术的儿科患者的病历进行了回顾性研究。该队列包括在2002年9月至2014年8月期间接受导管插入术的患者。年龄分布为新生儿至17岁。检索并分析了存档的比释动能面积乘积(PKA)和透视时间(T)读数。确定了累积有效剂量和各器官剂量。累积PKA水平在1.8至651.2 Gycm²之间,而累积有效剂量水平在2至259 mSv之间。累积透视时间显示在8.1至193.5分钟之间。累积器官剂量中位数在3至94 mGy之间。累积有效剂量水平高度可变,但可能超过250 mSv。尽管目前用于确定终身风险的方法并不完善,但各器官和有效剂量的测量对于机构间的比较仍然有用。